ATP-binding cassette sub-family G member 2
Details
- Name
- ATP-binding cassette sub-family G member 2
- Synonyms
- ABCP
- BCRP
- BCRP1
- Breast cancer resistance protein
- CDw338
- Mitoxantrone resistance-associated protein
- MXR
- Placenta-specific ATP-binding cassette transporter
- Urate exporter
- Gene Name
- ABCG2
- Organism
- Humans
- Amino acid sequence
>lcl|BSEQ0002125|ATP-binding cassette sub-family G member 2 MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS
- Number of residues
- 655
- Molecular Weight
- 72313.47
- Theoretical pI
- 8.9
- GO Classification
- FunctionsATP binding / ATPase activity, coupled to transmembrane movement of substances / heme transporter activity / protein homodimerization activity / transporter activity / xenobiotic-transporting ATPase activityProcessescellular iron ion homeostasis / drug transmembrane transport / heme transport / response to drug / small molecule metabolic process / transmembrane transport / transport / urate metabolic process / xenobiotic transportComponentsintegral component of membrane / mitochondrial membrane / nucleus / plasma membrane
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.
- Pfam Domain Function
- Transmembrane Regions
- 396-416 429-449 478-498 507-527 536-556 631-651
- Cellular Location
- Cell membrane
- Gene sequence
>lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2) ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC ATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT GGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA ATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA ACTATGCAACATGTACTGGCGAAGAATATTTGGTAA
- Chromosome Location
- 4
- Locus
- 4q22
- External Identifiers
Resource Link UniProtKB ID Q9UNQ0 UniProtKB Entry Name ABCG2_HUMAN GenBank Protein ID 4185796 GenBank Gene ID AF103796 GenAtlas ID ABCG2 HGNC ID HGNC:74 - General References
- Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998 Dec 1;58(23):5337-9. [Article]
- Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70. [Article]
- Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, Nishimura S: Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. 2001 Apr 1;61(7):2827-32. [Article]
- Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001 Sep;7(9):1028-34. [Article]
- Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB: The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 2003 Nov;17(14):2085-7. Epub 2003 Sep 4. [Article]
- Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article]
- Hillier LW, Graves TA, Fulton RS, Fulton LA, Pepin KH, Minx P, Wagner-McPherson C, Layman D, Wylie K, Sekhon M, Becker MC, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Kremitzki C, Oddy L, Du H, Sun H, Bradshaw-Cordum H, Ali J, Carter J, Cordes M, Harris A, Isak A, van Brunt A, Nguyen C, Du F, Courtney L, Kalicki J, Ozersky P, Abbott S, Armstrong J, Belter EA, Caruso L, Cedroni M, Cotton M, Davidson T, Desai A, Elliott G, Erb T, Fronick C, Gaige T, Haakenson W, Haglund K, Holmes A, Harkins R, Kim K, Kruchowski SS, Strong CM, Grewal N, Goyea E, Hou S, Levy A, Martinka S, Mead K, McLellan MD, Meyer R, Randall-Maher J, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Shah N, Swearengen-Shahid S, Snider J, Strong JT, Thompson J, Yoakum M, Leonard S, Pearman C, Trani L, Radionenko M, Waligorski JE, Wang C, Rock SM, Tin-Wollam AM, Maupin R, Latreille P, Wendl MC, Yang SP, Pohl C, Wallis JW, Spieth J, Bieri TA, Berkowicz N, Nelson JO, Osborne J, Ding L, Meyer R, Sabo A, Shotland Y, Sinha P, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Jones TA, She X, Ciccarelli FD, Izaurralde E, Taylor J, Schmutz J, Myers RM, Cox DR, Huang X, McPherson JD, Mardis ER, Clifton SW, Warren WC, Chinwalla AT, Eddy SR, Marra MA, Ovcharenko I, Furey TS, Miller W, Eichler EE, Bork P, Suyama M, Torrents D, Waterston RH, Wilson RK: Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature. 2005 Apr 7;434(7034):724-31. [Article]
- Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article]
- Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 1999 Jan 1;59(1):8-13. [Article]
- Schmitz G, Langmann T, Heimerl S: Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res. 2001 Oct;42(10):1513-20. [Article]
- Xu J, Liu Y, Yang Y, Bates S, Zhang JT: Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem. 2004 May 7;279(19):19781-9. Epub 2004 Mar 4. [Article]
- Diop NK, Hrycyna CA: N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry. 2005 Apr 12;44(14):5420-9. [Article]
- Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A: Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta. 2005 Feb 1;1668(1):53-63. [Article]
- Henriksen U, Gether U, Litman T: Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. J Cell Sci. 2005 Apr 1;118(Pt 7):1417-26. Epub 2005 Mar 15. [Article]
- Wakabayashi K, Nakagawa H, Tamura A, Koshiba S, Hoshijima K, Komada M, Ishikawa T: Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein. J Biol Chem. 2007 Sep 21;282(38):27841-6. Epub 2007 Aug 8. [Article]
- Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, Benjamin EJ, van Duijn CM, Witteman JC, Coresh J, Fox CS: Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008 Dec 6;372(9654):1953-61. doi: 10.1016/S0140-6736(08)61343-4. Epub 2008 Oct 1. [Article]
- Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M: Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10338-42. doi: 10.1073/pnas.0901249106. Epub 2009 Jun 8. [Article]
- Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, Ito K, Kusanagi Y, Chiba T, Tadokoro S, Takada Y, Oikawa Y, Inoue H, Suzuki K, Okada R, Nishiyama J, Domoto H, Watanabe S, Fujita M, Morimoto Y, Naito M, Nishio K, Hishida A, Wakai K, Asai Y, Niwa K, Kamakura K, Nonoyama S, Sakurai Y, Hosoya T, Kanai Y, Suzuki H, Hamajima N, Shinomiya N: Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med. 2009 Nov 4;1(5):5ra11. doi: 10.1126/scitranslmed.3000237. [Article]
- Desuzinges-Mandon E, Arnaud O, Martinez L, Huche F, Di Pietro A, Falson P: ABCG2 transports and transfers heme to albumin through its large extracellular loop. J Biol Chem. 2010 Oct 22;285(43):33123-33. doi: 10.1074/jbc.M110.139170. Epub 2010 Aug 12. [Article]
- Nakayama A, Matsuo H, Takada T, Ichida K, Nakamura T, Ikebuchi Y, Ito K, Hosoya T, Kanai Y, Suzuki H, Shinomiya N: ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans. Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1091-7. doi: 10.1080/15257770.2011.633953. [Article]
- Mo W, Zhang JT: Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 2012;3(1):1-27. Epub 2011 Mar 30. [Article]
- Zelinski T, Coghlan G, Liu XQ, Reid ME: ABCG2 null alleles define the Jr(a-) blood group phenotype. Nat Genet. 2012 Jan 15;44(2):131-2. doi: 10.1038/ng.1075. [Article]
- Saison C, Helias V, Ballif BA, Peyrard T, Puy H, Miyazaki T, Perrot S, Vayssier-Taussat M, Waldner M, Le Pennec PY, Cartron JP, Arnaud L: Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nat Genet. 2012 Jan 15;44(2):174-7. doi: 10.1038/ng.1070. [Article]
- Kobuchi H, Moriya K, Ogino T, Fujita H, Inoue K, Shuin T, Yasuda T, Utsumi K, Utsumi T: Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS One. 2012;7(11):e50082. doi: 10.1371/journal.pone.0050082. Epub 2012 Nov 26. [Article]
- Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y: Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet. 2002;47(6):285-310. [Article]
- Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Suzuki H, Sugiyama Y, Ozawa S, Sawada J: Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. Drug Metab Pharmacokinet. 2003;18(3):212-7. [Article]
- Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG: Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 2003 Jan;13(1):19-28. [Article]
- Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE: Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol. 2005 Aug;56(2):161-72. Epub 2005 Apr 19. [Article]
- Maekawa K, Itoda M, Sai K, Saito Y, Kaniwa N, Shirao K, Hamaguchi T, Kunitoh H, Yamamoto N, Tamura T, Minami H, Kubota K, Ohtsu A, Yoshida T, Saijo N, Kamatani N, Ozawa S, Sawada J: Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. Drug Metab Pharmacokinet. 2006 Apr;21(2):109-21. [Article]
Drug Relations
- Drug Relations
DrugBank ID Name Drug group Pharmacological action? Actions Details DB04851 Biricodar investigational unknown Details DB00317 Gefitinib approved, investigational unknown substrateinhibitor Details DB04216 Quercetin experimental, investigational unknown inhibitor Details DB03467 Naringenin experimental unknown inhibitor Details DB01030 Topotecan approved, investigational unknown substrate Details DB01051 Novobiocin approved, investigational, vet_approved, withdrawn unknown inhibitor Details DB00655 Estrone approved unknown inhibitor Details DB01232 Saquinavir approved, investigational unknown inhibitor Details DB00338 Omeprazole approved, investigational, vet_approved unknown inhibitor Details DB01094 Hesperetin experimental unknown inhibitor Details DB01645 Genistein investigational unknown inhibitor Details DB00220 Nelfinavir approved no inhibitor Details DB01016 Glyburide approved unknown substrate Details DB00255 Diethylstilbestrol approved, investigational, withdrawn unknown inhibitor Details DB00503 Ritonavir approved, investigational unknown inhibitor Details DB00175 Pravastatin approved no substrate Details DB00997 Doxorubicin approved, investigational unknown substrate Details DB00213 Pantoprazole approved unknown substrateinhibitor Details DB00091 Cyclosporine approved, investigational, vet_approved unknown inhibitor Details DB04348 Taurocholic acid approved, experimental unknown inhibitor Details DB00619 Imatinib approved no substrateinhibitor Details DB00783 Estradiol approved, investigational, vet_approved unknown inhibitor Details DB01204 Mitoxantrone approved, investigational unknown substrate Details DB02115 Daidzin experimental unknown inhibitor Details DB00398 Sorafenib approved, investigational unknown substrateinhibitor Details DB01268 Sunitinib approved, investigational unknown inhibitor Details DB00470 Dronabinol approved, illicit no inhibitor Details DB00921 Buprenorphine approved, illicit, investigational, vet_approved unknown inhibitor Details DB00795 Sulfasalazine approved no substrateinhibitor Details DB00966 Telmisartan approved, investigational unknown inhibitor Details DB01234 Dexamethasone approved, investigational, vet_approved unknown inhibitor Details DB01254 Dasatinib approved, investigational unknown substrateinhibitor Details DB00457 Prazosin approved unknown substrate Details DB00448 Lansoprazole approved, investigational unknown inhibitor Details DB01129 Rabeprazole approved, investigational unknown inhibitor Details DB04881 Elacridar investigational unknown inhibitor Details DB04868 Nilotinib approved, investigational unknown substrateinhibitor Details DB00530 Erlotinib approved, investigational unknown inhibitor Details DB05294 Vandetanib approved unknown inhibitor Details DB00709 Lamivudine approved, investigational unknown substrate Details DB00762 Irinotecan approved, investigational unknown substrate Details DB00773 Etoposide approved unknown substrate Details DB00970 Dactinomycin approved, investigational unknown substrate Details DB00286 Conjugated estrogens approved unknown substrate Details DB00439 Cerivastatin approved, withdrawn unknown substrate Details DB00624 Testosterone approved, investigational unknown substrate Details DB00675 Tamoxifen approved unknown substrate Details DB00669 Sumatriptan approved, investigational unknown substrate Details DB00694 Daunorubicin approved unknown substrate Details DB04540 Cholesterol approved, investigational unknown inducer Details DB00563 Methotrexate approved unknown substrate Details DB00158 Folic acid approved, nutraceutical, vet_approved unknown substrate Details DB03496 Alvocidib experimental, investigational unknown substrate Details DB00541 Vincristine approved, investigational unknown substrate Details DB00444 Teniposide approved unknown substrate Details DB00698 Nitrofurantoin approved, vet_approved unknown substrate Details DB00602 Ivermectin approved, investigational, vet_approved unknown substrate Details DB04690 Camptothecin experimental unknown substrate Details DB00740 Riluzole approved, investigational unknown substrate Details DB00242 Cladribine approved, investigational unknown substrate Details DB00631 Clofarabine approved, investigational unknown substrate Details DB00526 Oxaliplatin approved, investigational no substrate Details DB06772 Cabazitaxel approved unknown inhibitor Details DB08860 Pitavastatin approved unknown substrate Details DB06589 Pazopanib approved unknown substrate Details DB08864 Rilpivirine approved unknown inhibitor Details DB08880 Teriflunomide approved unknown substrateinhibitor Details DB01097 Leflunomide approved, investigational unknown substrate Details DB08881 Vemurafenib approved unknown substrateinhibitor Details DB06605 Apixaban approved unknown substrate Details DB08828 Vismodegib approved, investigational unknown inhibitor Details DB08896 Regorafenib approved unknown inhibitor Details DB08901 Ponatinib approved, investigational unknown substrateinhibitor Details DB00973 Ezetimibe approved unknown substrate Details DB08912 Dabrafenib approved, investigational no substrateinhibitor Details DB00549 Zafirlukast approved, investigational unknown antagonist Details DB00285 Venlafaxine approved unknown inducer Details DB00495 Zidovudine approved unknown substrate Details DB08916 Afatinib approved unknown substrateinhibitor Details DB00544 Fluorouracil approved unknown substrate Details DB00688 Mycophenolate mofetil approved, investigational unknown substrate Details DB00515 Cisplatin approved unknown substrate Details DB00958 Carboplatin approved unknown substrate Details DB01098 Rosuvastatin approved unknown substrate Details DB01248 Docetaxel approved, investigational unknown substrate Details DB08934 Sofosbuvir approved no substrate Details DB09078 Lenvatinib approved, investigational no substrate Details DB09054 Idelalisib approved no substrate Details DB09065 Cobicistat approved unknown inhibitor Details DB09291 Rolapitant approved, investigational no inhibitor Details DB09102 Daclatasvir approved, investigational unknown inhibitor Details DB05239 Cobimetinib approved, investigational no weak inhibitor Details DB09330 Osimertinib approved no substrate Details DB11363 Alectinib approved, investigational no inhibitor Details DB08931 Riociguat approved no substrate Details DB09183 Dasabuvir approved unknown inhibitor Details DB06654 Safinamide approved, investigational unknown inhibitor Details DB11613 Velpatasvir approved, investigational no substrateinhibitor Details DB06290 Simeprevir approved unknown substrateinhibitor Details DB09027 Ledipasvir approved no transporter Details DB09296 Ombitasvir approved, investigational no substrate Details DB11943 Delafloxacin approved, investigational no substrate Details DB01685 Topiroxostat experimental unknown inhibitor Details DB12026 Voxilaprevir approved, investigational no substrateinhibitor Details DB13874 Enasidenib approved, investigational unknown substrateinhibitor Details DB13878 Pibrentasvir approved, investigational unknown substrateinhibitor Details DB13879 Glecaprevir approved, investigational unknown substrateinhibitor Details DB12483 Copanlisib approved, investigational unknown substrate Details DB12001 Abemaciclib approved, investigational unknown substrateinhibitor Details DB12070 Letermovir approved, investigational no inhibitor Details DB12267 Brigatinib approved, investigational no substrateinhibitor Details DB08930 Dolutegravir approved no substrate Details DB12332 Rucaparib approved, investigational no substrateinhibitor Details DB11817 Baricitinib approved, investigational unknown substrateinhibitor Details DB09061 Cannabidiol approved, investigational unknown inhibitor Details DB11827 Ertugliflozin approved, investigational unknown substrate Details DB13943 Testosterone cypionate approved unknown substrate Details DB13944 Testosterone enanthate approved unknown substrate Details DB13946 Testosterone undecanoate approved, investigational unknown substrate Details DB13952 Estradiol acetate approved, investigational, vet_approved unknown inhibitor Details DB13953 Estradiol benzoate approved, investigational, vet_approved unknown inhibitor Details DB13954 Estradiol cypionate approved, investigational, vet_approved unknown inhibitor Details DB13955 Estradiol dienanthate approved, investigational, vet_approved unknown inhibitor Details DB13956 Estradiol valerate approved, investigational, vet_approved unknown inhibitor Details DB11901 Apalutamide approved, investigational unknown inducer Details DB11633 Isavuconazole approved, investigational unknown inhibitor Details DB14011 Nabiximols investigational unknown inhibitor Details DB14009 Medical Cannabis experimental, investigational unknown inhibitor Details DB12010 Fostamatinib approved, investigational no inhibitor Details DB11995 Avatrombopag approved, investigational unknown inhibitor Details DB09297 Paritaprevir approved, investigational unknown inhibitor Details DB14538 Hydrocortisone aceponate experimental, vet_approved unknown Details DB14539 Hydrocortisone acetate approved, vet_approved unknown Details DB14540 Hydrocortisone butyrate approved, vet_approved unknown Details DB14541 Hydrocortisone cypionate approved, investigational, vet_approved unknown Details DB14542 Hydrocortisone phosphate approved, vet_approved unknown Details DB14543 Hydrocortisone probutate approved, vet_approved unknown Details DB14544 Hydrocortisone valerate approved, vet_approved unknown Details DB05928 Dovitinib investigational unknown inhibitorinducer Details DB13125 Lusutrombopag approved, investigational unknown substrate Details DB06210 Eltrombopag approved unknown inhibitor Details DB00396 Progesterone approved, vet_approved unknown inhibitorinducer Details DB02703 Fusidic acid approved, investigational unknown inhibitor Details DB11952 Duvelisib approved, investigational no substrate Details DB11760 Talazoparib approved, investigational unknown substrate Details DB11963 Dacomitinib approved, investigational no substrateinhibitor Details DB11581 Venetoclax approved, investigational unknown inhibitor Details DB11855 Revefenacin approved, investigational no substrate Details DB12141 Gilteritinib approved, investigational no inhibitor Details DB06228 Rivaroxaban approved unknown substrate Details DB09279 Fimasartan investigational unknown substrate Details DB11978 Glasdegib approved, investigational no substrateinhibitor Details DB09074 Olaparib approved no inhibitor Details DB00437 Allopurinol approved unknown substrate Details DB09073 Palbociclib approved, investigational no substrateinhibitor Details DB08907 Canagliflozin approved unknown Details DB01079 Tegaserod approved, investigational, withdrawn unknown substrate Details DB09299 Tenofovir alafenamide approved no substrate Details DB00481 Raloxifene approved, investigational unknown substrate Details DB12015 Alpelisib approved, investigational unknown substrate Details DB00394 Beclomethasone dipropionate approved, investigational unknown inhibitor Details DB00482 Celecoxib approved, investigational unknown substrate Details DB00843 Donepezil approved unknown substrate Details DB12500 Fedratinib approved, investigational unknown inhibitor Details DB11757 Istradefylline approved, investigational unknown inhibitor Details DB09079 Nintedanib approved unknown Details DB00201 Caffeine approved unknown inhibitor Details DB11732 Lasmiditan approved, investigational unknown inhibitor Details DB14962 Trastuzumab deruxtecan approved, investigational unknown substrate Details DB12941 Darolutamide approved, investigational unknown substrateinhibitor Details DB15091 Upadacitinib approved, investigational no substrateinhibitor Details DB15328 Ubrogepant approved, investigational unknown substrate Details DB15233 Avapritinib approved, investigational unknown inhibitormodulator Details DB11644 Tafamidis approved, investigational unknown inhibitor Details DB12887 Tazemetostat approved, investigational unknown substrate Details DB14723 Larotrectinib approved, investigational unknown substrate Details DB11712 Tezacaftor approved, investigational no substrateinhibitor Details DB12457 Rimegepant approved, investigational unknown substrate Details DB12612 Ozanimod approved, investigational unknown substrate Details DB01708 Prasterone approved, investigational, nutraceutical unknown substrate Details DB11689 Selumetinib approved, investigational unknown substrate Details DB11652 Tucatinib approved, investigational unknown substrate Details DB15102 Pemigatinib approved, investigational no substrate Details DB11791 Capmatinib approved, investigational unknown inhibitor Details DB06813 Pralatrexate approved, investigational no substrate Details DB15685 Selpercatinib approved, investigational unknown substrateinhibitor Details DB14840 Ripretinib approved unknown substrateinhibitor Details DB00845 Clofazimine approved, investigational unknown inhibitor Details DB09038 Empagliflozin approved unknown substrate Details DB09274 Artesunate approved, investigational unknown substrate Details DB14649 Dexamethasone acetate approved, investigational, vet_approved unknown inhibitor Details DB11796 Fostemsavir approved, investigational unknown substrateinhibitor Details DB15305 Risdiplam approved, investigational unknown substrate Details DB11820 Nifurtimox approved, investigational unknown substrate Details DB15822 Pralsetinib approved, investigational no substrateinhibitor Details DB06448 Lonafarnib approved, investigational no inhibitor Details DB15982 Berotralstat approved unknown substrate Details DB11853 Relugolix approved, investigational unknown inhibitor Details DB11632 Opicapone approved, investigational no substrate Details DB15456 Vericiguat approved, investigational unknown substrate Details DB11751 Cabotegravir approved, investigational unknown substrate Details DB15133 Tepotinib approved, investigational no inhibitor Details DB15442 Trilaciclib approved, investigational unknown substrate Details DB00391 Sulpiride approved, investigational unknown substrate Details DB00853 Temozolomide approved, investigational no substrate Details DB06237 Avanafil approved unknown inhibitor Details DB04854 Febuxostat approved no inhibitor Details DB11800 Tivozanib approved, investigational no inhibitor Details DB06288 Amisulpride approved, investigational no substrate Details DB15569 Sotorasib approved, investigational unknown inhibitor Details DB11886 Infigratinib approved, investigational no substrateinhibitor Details DB12151 Brincidofovir approved, investigational no inhibitor Details DB16703 Belumosudil approved, investigational no inhibitor Details DB16390 Mobocertinib approved, investigational unknown inhibitor Details DB16098 Atogepant approved, investigational no substrate Details DB12597 Asciminib approved, investigational no substrateinhibitor Details DB06234 Maribavir approved, investigational no inhibitor Details DB12713 Sotagliflozin approved, investigational no inhibitor Details DB04847 Roxadustat approved, investigational unknown inhibitor Details DB14737 Cannabinol experimental, investigational unknown inhibitor Details DB11697 Pacritinib approved, investigational no inhibitor Details DB13055 Oteseconazole approved, investigational no inhibitor Details DB16407 Azvudine investigational unknown regulator Details DB12020 Tecovirimat approved, investigational unknown inhibitor Details DB09118 Stiripentol approved unknown inhibitor Details DB13997 Baloxavir marboxil approved, investigational unknown inhibitor Details DB16650 Deucravacitinib approved, investigational unknown substrateinhibitor Details DB12095 Telotristat ethyl approved, investigational no binder Details DB15149 Futibatinib approved, investigational no substrate Details DB17083 Linzagolix approved no substrate Details DB11793 Niraparib approved, investigational no substrateinhibitor Details DB00642 Pemetrexed approved, investigational no Details DB16267 Olutasidenib approved, investigational no inhibitor Details DB17472 Pirtobrutinib approved, investigational unknown substrateinhibitor Details DB06374 Elacestrant approved, investigational unknown inhibitor Details DB11682 Daprodustat approved, investigational no substrate Details DB12548 Sparsentan approved, investigational unknown substrateinhibitor Details DB16217 Leniolisib approved, investigational no substrateinhibitor Details DB01238 Aripiprazole approved, investigational unknown Details DB12255 Vadadustat approved, investigational unknown inhibitor Details DB12874 Quizartinib approved, investigational no inhibitor Details DB05467 Palovarotene approved, investigational no inhibitor Details DB11763 Momelotinib investigational unknown substrateinhibitor Details